Physician profile
Daniel R Humer
NPI 1003053554
$69,338.71
in general payments reported to CMS, 2019-2025
32 companies · $38K in 2025
The $38K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,203 · 2022: $1,154 · 2023: $3,997 · 2024: $25K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Consulting Fee: $16K · Food and Beverage: $10K · Travel and Lodging: $3,398 · Honoraria: $2,025 · Education: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,165.00 |
| Consulting Fee | $15,601.42 |
| Food and Beverage | $10,324.28 |
| Travel and Lodging | $3,397.95 |
| Honoraria | $2,025.00 |
| Education | $467.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $46,690.06 | 2021-2025 | Rybrevant, Carvykti, Erleada |
| Janssen Scientific Affairs, LLC | $6,981.47 | 2023-2025 | Erleada, Akeega |
| Dendreon Pharmaceuticals LLC | $4,635.55 | 2021-2025 | Provenge |
| Accord Healthcare, INC. | $3,102.76 | 2023-2024 | |
| Urogen Pharma, INC. | $1,089.17 | 2022-2025 | |
| Astellas Pharma US INC | $1,084.82 | 2021-2025 | Xtandi, Myrbetriq |
| Ferring Pharmaceuticals INC. | $830.32 | 2024-2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $568.72 | 2021-2025 | |
| Myovant Sciences INC. | $485.06 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $476.48 | 2023-2024 | Opdivo |
| Novartis Pharmaceuticals Corporation | $469.43 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $454.24 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $419.92 | 2021-2025 | |
| Boston Scientific Corporation | $349.91 | 2022-2025 | Axonics, General - Kidney Stone Disease |
| Medtronic, INC. | $280.31 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $230.91 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Axonics, INC. | $206.92 | 2021-2024 | Bulkamid, Axonics |
| Abbvie INC. | $176.53 | 2023-2025 | |
| Olympus America INC. | $136.26 | 2024-2025 | Itind System |
| Astrazeneca Pharmaceuticals LP | $133.16 | 2023-2024 | Lynparza |
| Progenics Pharmaceuticals, INC. | $87.02 | 2023 | Pylarify |
| Amgen INC. | $81.99 | 2022 | |
| Endo Pharmaceuticals INC. | $80.55 | 2021 | |
| Tolmar, INC. | $78.50 | 2023 | |
| Antares Pharma, INC. | $38.22 | 2022-2023 | Xyosted, Nocdurna, Tlando |
| Foundation Medicine, INC. | $35.71 | 2022-2023 | |
| Abc Home Medical Supply, INC. | $26.16 | 2022 | |
| 180 Medical, INC. | $25.68 | 2024 | |
| Myriad Genetic Laboratories, INC. | $23.89 | 2022 | |
| Coloplast Corp | $22.81 | 2024 | |
| Teleflex LLC | $21.64 | 2025 | Urolift |
| Allergan, INC. | $14.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Humer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.